Conformational transition pathway of R308K mutant glucokinase in presence of the glucokinase activator YNKGKA4

0
1
Upvote 0 Comment

Dear Sir,

I am Pradeepkiran an early researcher and I published a paper in FEBSOpenBio with title :

Conformational transition pathway of R308K mutant glucokinase in presence of the glucokinase activator YNKGKA4" and asking to wave the fee access many times but they won't be wave off.

I think this is bad situation for me in the research field, i strongly believe the Wiley publishers running the journals for the good impact and importance to the scientific values, not to run the journals for money.

Go to the profile of Pradeepkiran Jangampalli Adi

Pradeepkiran Jangampalli Adi

Postdoc, Texas Tech Health Science Center

1 Comments

Go to the profile of Mary Purton
Mary Purton 7 days ago

FEBS publishes four journals as part of its core objectives as a charity, to promote and support biochemistry, molecular biology, cell biology, molecular biophysics and related research areas.  The journals also provide an income which funds the other programmes of FEBS such as its Congress, Advanced Courses, and Fellowships.


FEBS Press offers authors a choice of publication routes.  The FEBS Journal and FEBS Letters are supported by library subscriptions and levy no charges for authors. 


Molecular Oncology and FEBS Open Bio are open access journals that charge authors a publication fee but are free to all to read and distribute.  Authors from countries eligible for the Research4Life (http://www.research4life.org/) programs will not be charged, or will receive a substantial discount. For more information, see https://authorservices.wiley.com/open-science/open-access/for-authors/publication-charges/waivers-and-discounts.html

Dear Dr Pradeepkiran - our publishers, Wiley, will be in contact with you directly about your article in FEBS Open Bio.